On the regulatory level, mutations in the CFH gene and anti-CFH autoantibodies have been identified in the C3 glomerulopathy patients and related to pathogenesis of the disease (Appel et al. 2005; Goodship et al. 2012; Licht and Fremeaux-Bacchi 2009; Zhang et al. 2012). The gene discussed is CFH; the disease is complement 3 glomerulopathy.